Dengue Virus Type 2 Vaccine: Reactogenicity and Immunogenicity in Soldiers
| Autor: | Peter L. Summers, Robert Scott, K. D. T. Jesrani, Thomas E. Simms, William H. Bancroft, Philip K. Russell, Doria R. Dubois, Kenneth H. Eckels, Charles H. Hoke, D. Tsoulos |
|---|---|
| Rok vydání: | 1984 |
| Předmět: |
Adult
Male Adolescent Dengue virus Antibodies Viral Vaccines Attenuated medicine.disease_cause Leukocyte Count Double-Blind Method Neutralization Tests medicine Humans Immunology and Allergy Seroconversion Military Medicine Neutralizing antibody Clinical Trials as Topic Reactogenicity biology business.industry Immunogenicity Vaccination Yellow fever Viral Vaccines Dengue Virus Hemagglutination Inhibition Tests Middle Aged medicine.disease Virology Infectious Diseases Immunization biology.protein Yellow fever virus business |
| Zdroj: | Journal of Infectious Diseases. 149:1005-1010 |
| ISSN: | 1537-6613 0022-1899 |
| DOI: | 10.1093/infdis/149.6.1005 |
| Popis: | A live dengue virus type 2 (dengue-2) vaccine (PR-159/S-1) was tested for reactogenicity and immunogenicity in a placebo-controlled, double-blind clinical trial involving 98 soldiers. Seroconversion rates based on the development of neutralizing antibody to dengue-2 were 90% in 70 recipients with immunity to yellow fever and 61% in 28 vaccinees without such immunity (P less than .01). Peak titers of neutralizing antibody were three times higher in recipients with antibody to yellow fever virus and persisted in most for at least 18 months. Individuals seroconverting to the vaccine virus more frequently experienced systemic symptoms than those who received placebo (P less than .02). Future users of this dengue-2 vaccine may wish to employ immunization schedules that include preliminary immunization against yellow fever and must be prepared to accept mild vaccine-related symptoms in some recipients. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|